Risk factors of relapse following glucocorticoid tapering in IgG4-related disease

T. Sasaki, M. Akiyama, Yuko Kaneko, Hidekata Yasuoka, Katsuya Suzuki, Kunihiro Yamaoka, Tsutomu Takeuchi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective. To identify risk factors of relapse in IgG4-related disease (IgG4-RD) during glucocorticoid (GC) tapering. Methods. A total of 27 consecutive patients with IgG4-RD (7 with and 20 without relapse) treated with GC for more than 6 months were enrolled. Baseline characteristics were compared in patients with and without relapse. Longitudinal analysis was also performed. Results. Patients with relapse had significantly higher levels of serum IgG4 (816.0 vs. 346.5 mg/dL, p=0.048) and number of organs involved (5 vs. 3, p=0.008) and lower levels of serum IgA (82 vs. 176 mg/dL, p=0.002) at baseline, compared to patients without relapse. The most useful cut-off value of baseline serum IgG4 to predictive relapse was 813 mg/dl with a sensitivity of 57.1% and a specificity of 95.0%. In longitudinal analysis, serum IgG4 decreased at 6 months after treatment in both groups, but was elevated at relapse in patients with relapse, while remaining low in those without relapse. Conclusion. Higher levels of serum IgG4 at baseline were associated with relapse in IgG4-RD. Re-elevation of serum IgG4 levels during GC treatment reflected disease relapse.

Original languageEnglish
Pages (from-to)S186-S189
JournalClinical and Experimental Rheumatology
Volume36
Publication statusPublished - 2018 Jan 1

Fingerprint

Glucocorticoids
Immunoglobulin G
Recurrence
Serum
Immunoglobulin A
Therapeutics

Keywords

  • Glucocorticoid
  • IgG4
  • IgG4-related disease
  • Relapse
  • Risk factor

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Risk factors of relapse following glucocorticoid tapering in IgG4-related disease. / Sasaki, T.; Akiyama, M.; Kaneko, Yuko; Yasuoka, Hidekata; Suzuki, Katsuya; Yamaoka, Kunihiro; Takeuchi, Tsutomu.

In: Clinical and Experimental Rheumatology, Vol. 36, 01.01.2018, p. S186-S189.

Research output: Contribution to journalArticle

@article{c3006d59e7f34c719b94f1764359cb62,
title = "Risk factors of relapse following glucocorticoid tapering in IgG4-related disease",
abstract = "Objective. To identify risk factors of relapse in IgG4-related disease (IgG4-RD) during glucocorticoid (GC) tapering. Methods. A total of 27 consecutive patients with IgG4-RD (7 with and 20 without relapse) treated with GC for more than 6 months were enrolled. Baseline characteristics were compared in patients with and without relapse. Longitudinal analysis was also performed. Results. Patients with relapse had significantly higher levels of serum IgG4 (816.0 vs. 346.5 mg/dL, p=0.048) and number of organs involved (5 vs. 3, p=0.008) and lower levels of serum IgA (82 vs. 176 mg/dL, p=0.002) at baseline, compared to patients without relapse. The most useful cut-off value of baseline serum IgG4 to predictive relapse was 813 mg/dl with a sensitivity of 57.1{\%} and a specificity of 95.0{\%}. In longitudinal analysis, serum IgG4 decreased at 6 months after treatment in both groups, but was elevated at relapse in patients with relapse, while remaining low in those without relapse. Conclusion. Higher levels of serum IgG4 at baseline were associated with relapse in IgG4-RD. Re-elevation of serum IgG4 levels during GC treatment reflected disease relapse.",
keywords = "Glucocorticoid, IgG4, IgG4-related disease, Relapse, Risk factor",
author = "T. Sasaki and M. Akiyama and Yuko Kaneko and Hidekata Yasuoka and Katsuya Suzuki and Kunihiro Yamaoka and Tsutomu Takeuchi",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "36",
pages = "S186--S189",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",

}

TY - JOUR

T1 - Risk factors of relapse following glucocorticoid tapering in IgG4-related disease

AU - Sasaki, T.

AU - Akiyama, M.

AU - Kaneko, Yuko

AU - Yasuoka, Hidekata

AU - Suzuki, Katsuya

AU - Yamaoka, Kunihiro

AU - Takeuchi, Tsutomu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective. To identify risk factors of relapse in IgG4-related disease (IgG4-RD) during glucocorticoid (GC) tapering. Methods. A total of 27 consecutive patients with IgG4-RD (7 with and 20 without relapse) treated with GC for more than 6 months were enrolled. Baseline characteristics were compared in patients with and without relapse. Longitudinal analysis was also performed. Results. Patients with relapse had significantly higher levels of serum IgG4 (816.0 vs. 346.5 mg/dL, p=0.048) and number of organs involved (5 vs. 3, p=0.008) and lower levels of serum IgA (82 vs. 176 mg/dL, p=0.002) at baseline, compared to patients without relapse. The most useful cut-off value of baseline serum IgG4 to predictive relapse was 813 mg/dl with a sensitivity of 57.1% and a specificity of 95.0%. In longitudinal analysis, serum IgG4 decreased at 6 months after treatment in both groups, but was elevated at relapse in patients with relapse, while remaining low in those without relapse. Conclusion. Higher levels of serum IgG4 at baseline were associated with relapse in IgG4-RD. Re-elevation of serum IgG4 levels during GC treatment reflected disease relapse.

AB - Objective. To identify risk factors of relapse in IgG4-related disease (IgG4-RD) during glucocorticoid (GC) tapering. Methods. A total of 27 consecutive patients with IgG4-RD (7 with and 20 without relapse) treated with GC for more than 6 months were enrolled. Baseline characteristics were compared in patients with and without relapse. Longitudinal analysis was also performed. Results. Patients with relapse had significantly higher levels of serum IgG4 (816.0 vs. 346.5 mg/dL, p=0.048) and number of organs involved (5 vs. 3, p=0.008) and lower levels of serum IgA (82 vs. 176 mg/dL, p=0.002) at baseline, compared to patients without relapse. The most useful cut-off value of baseline serum IgG4 to predictive relapse was 813 mg/dl with a sensitivity of 57.1% and a specificity of 95.0%. In longitudinal analysis, serum IgG4 decreased at 6 months after treatment in both groups, but was elevated at relapse in patients with relapse, while remaining low in those without relapse. Conclusion. Higher levels of serum IgG4 at baseline were associated with relapse in IgG4-RD. Re-elevation of serum IgG4 levels during GC treatment reflected disease relapse.

KW - Glucocorticoid

KW - IgG4

KW - IgG4-related disease

KW - Relapse

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=85055615616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055615616&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - S186-S189

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

ER -